EP Patent

EP2504332B2 — An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Assigned to Genzyme Corp · Expires 2021-03-17 · 5y expired

What this patent protects

Patent listed against eliglustat-tartrate.

Drugs covered by this patent

eliglustat-tartrate (ELIGLUSTAT TARTRATE)

Patent Metadata

Patent number: EP2504332B2
Jurisdiction: EP
Classification: —
Expires: 2021-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Genzyme Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.